Recent 8-K filings for EIKN

• June 10, 2026, 4:15 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

  Eikon Therapeutics appoints Ma. Fatima D. Francisco to Board as Class I director

  Appointment effective June 15, 2026; serves until 2027 annual meeting.

• June 1, 2026, 7:30 AM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

  TeLuRide-005 Phase 2: ORR 63.1%, DCR 90.8% in 1L stage 4 NSCLC (n=65 evaluable).

• May 11, 2026, 4:05 PM ET earnings materiality 0.80 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Eikon Therapeutics Q1 2026 net loss $83M, cash $596M; three oncology programs advance

  Net loss $83M (Q1 2026) vs $74.5M (Q1 2025); R&D expenses $70M (+24%) incl. $5M milestone to Impact Therapeutics.

• March 30, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Eikon Therapeutics reports Q4/FY2025 net loss $79.7M/$333.6M; IPO raised $381M

  Net loss attributable to common stockholders was $79.7M in Q4 2025 and $333.6M for full year 2025.

• February 6, 2026, 6:59 PM ET other material materiality 0.40 neutral item 5.03item 9.01 ◈ Governance Changes ×2

  Eikon adopts amended charter and bylaws upon IPO closing on Feb 6, 2026

  IPO of common stock closed on February 6, 2026 per the company's S-1 registration.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event other_material

1 positive 0 negative 4 neutral

source · EIKN on sec.gov